Economic Analysis of Carboplatin Versus Cisplatin in Lung and Ovarian Cancer

Author： Khan Z.M.   Rascati K.L.   Koeller J.M.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.16, Iss.1, 1999-07, pp. : 43-57

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pemetrexed plus either cisplatin or carboplatin are active and well tolerated first-line treatments of extensive-stage small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

A Phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer

By Sunpaweravong Patrapim   Magree Lyn   Rabinovitch Rachel   Bunn Paul   Kelly Karen  

Investigational New Drugs, Vol. 24, Iss. 3, 2006-05 ,pp. : 213-221

Springer Publishing Company

Access to resources Recommend Favorite

Docetaxel/carboplatin combo delivers in ovarian cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 631, 2011-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Gemcitabine enhances carboplatin for recurrent ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1557, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

QOL better with carboplatin + paclitaxel for ovarian cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 498, 2006-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite